No significant differences were, however, noted between MC1R‐R‐carriers and non‐carriers in the frequency of the tumor BRAF mutations (43.6% vs. 53.1%, p = 0.361) or BRAF(±MEK) inhibitors received in previous or later treatment lines (Table S1). Here, BRAF is linked to neoplasm.